{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T20:49:42Z","timestamp":1720990182190},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,9]],"date-time":"2011-10-09T00:00:00Z","timestamp":1318118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00280-011-1754-1","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T14:21:14Z","timestamp":1318083674000},"page":"281-287","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma"],"prefix":"10.1007","volume":"69","author":[{"given":"David A.","family":"Reardon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Rich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. K.","family":"Alfred Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotus","family":"Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"DiLea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Mietlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,9]]},"reference":[{"key":"1754_CR1","first-page":"2231","volume":"48","author":"PA Humphrey","year":"1998","unstructured":"Humphrey PA, Wong AJ, Vogelstein B et al (1998) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231\u20132238","journal-title":"Cancer Res"},{"key":"1754_CR2","first-page":"1383","volume":"60","author":"L Frederick","year":"2000","unstructured":"Frederick L, Wang XY, Eley G et al (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383\u20131387","journal-title":"Cancer Res"},{"key":"1754_CR3","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc Natl Acad Sci USA 98:10314\u201310319","journal-title":"Proc Natl Acad Sci USA"},{"key":"1754_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s004010051199","volume":"100","author":"G Stockhammer","year":"2000","unstructured":"Stockhammer G, Obwegeser A, Kostron H et al (2000) Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol 100:101\u2013105","journal-title":"Acta Neuropathol"},{"key":"1754_CR5","first-page":"8930","volume":"63","author":"QW Fan","year":"2003","unstructured":"Fan QW, Specht KM, Zhang C et al (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway-A chemical genetic approach. Cancer Res 63:8930\u20138938","journal-title":"Cancer Res"},{"key":"1754_CR6","first-page":"4340","volume":"9","author":"QB She","year":"2003","unstructured":"She QB, Solit D, Basso A et al (2003) Resistance to gefitinib in PTEN-null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3\u2032-kinase\/Akt pathway signaling. Clin Cancer Res 9:4340\u20134346","journal-title":"Clin Cancer Res"},{"key":"1754_CR7","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/sj.onc.1206388","volume":"22","author":"R Bianco","year":"2003","unstructured":"Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN\/MMAC1\/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812\u20132822","journal-title":"Oncogene"},{"key":"1754_CR8","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina K, Lee RT, Politis C et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten \u00b1 mice. Proc Natl Acad Sci USA 98:10320\u201310325","journal-title":"Proc Natl Acad Sci USA"},{"key":"1754_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.101.4.1","volume":"4","author":"RK Goudar","year":"2005","unstructured":"Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma multiforme tumor growth inhibition. Mol Cancer Ther 4:101\u2013112","journal-title":"Mol Cancer Ther"},{"key":"1754_CR10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-09-0388","volume":"8","author":"I Nakachi","year":"2010","unstructured":"Nakachi I, Naoki K, Soejima K et al (2010) The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib-resistant lung cancer cell line through c-Met inhibition. Mol Cancer Res 8:1142\u20131151","journal-title":"Mol Cancer Res"},{"key":"1754_CR11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/13543784.11.12.1845","volume":"11","author":"B Nashan","year":"2002","unstructured":"Nashan B (2002) Review of the proliferation inhibitor everolimus. Exp Opin Investig Drugs 11:1845\u20131857","journal-title":"Exp Opin Investig Drugs"},{"key":"1754_CR12","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA III et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588\u20131595","journal-title":"J Clin Oncol"},{"key":"1754_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1541-0420.00058","volume":"59","author":"PF Thall","year":"2003","unstructured":"Thall PF, Millikan RE, Mueller P et al (2003) Dose-finding with two agents in phase I oncology trials. Biometrics 59:487\u2013496","journal-title":"Biometrics"},{"key":"1754_CR14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17:1103\u20131120","journal-title":"Stat Med"},{"key":"1754_CR15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"1754_CR16","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316771","volume-title":"Statistical intervals: a guide for practioners","author":"GJ Hahn","year":"1991","unstructured":"Hahn GJ, Meeker WQ (1991) Statistical intervals: a guide for practioners. Wiley, New York"},{"key":"1754_CR17","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","volume":"115","author":"RJ Amato","year":"2009","unstructured":"Amato RJ, Jac J, Giessinger S et al (2009) A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115:2438\u20132446","journal-title":"Cancer"},{"key":"1754_CR18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","volume":"27","author":"BM Wolpin","year":"2008","unstructured":"Wolpin BM, Hezel AF, Abrams T et al (2008) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27:193\u2013198","journal-title":"J Clin Oncol"},{"key":"1754_CR19","unstructured":"Patnaik A, Ricart A, Cooper J et al. (2007) A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multitargeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 25(suppl 18):141\u00a0s. abstract 3512"},{"key":"1754_CR20","doi-asserted-by":"crossref","unstructured":"Chang SM, Kuhn J, Lamborn T et al. (2009) Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG)(NABTC 04\u201302). J Clin Oncol 27(suppl 15):88\u00a0s. abstract 2004","DOI":"10.1200\/jco.2009.27.15_suppl.2004"},{"key":"1754_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","volume":"7","author":"PH Patel","year":"2009","unstructured":"Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7:24\u201327","journal-title":"Clin Genitourin Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1754-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1754-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:50:50Z","timestamp":1686390650000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1754-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1754-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,9]]}}}